Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) dropped 3% during trading on Tuesday . The stock traded as low as $1.44 and last traded at $1.44. Approximately 51,537 shares were traded during mid-day trading, an increase of 22% from the average daily volume of 42,244 shares. The stock had previously closed at $1.49.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research report on Thursday, June 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Saturday, September 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.50.
Check Out Our Latest Research Report on APRE
Aprea Therapeutics Price Performance
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.24. The company had revenue of $0.12 million during the quarter. Aprea Therapeutics had a negative net margin of 1,645.01% and a negative return on equity of 78.90%. Analysts forecast that Aprea Therapeutics, Inc. will post -2.55 earnings per share for the current year.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Read More
- Five stocks we like better than Aprea Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector
- Trading Stocks: RSI and Why it’s Useful
- These Are the 3 Hottest Sectors for Q3 Earnings Growth
- What is the Dogs of the Dow Strategy? Overview and Examples
- AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
